Related Experiment Videos
[Clinical experiences with mefloquine in tropical malaria--a prospective study]
T Held1, M Trautmann, T Weinke
1Universitätsklinikum Rudolf Virchow, Abteilung für Innere Medizin mit Schwerpunkt Infektionskrankheiten, Berlin.
Immunitat Und Infektion
|June 1, 1991
Summary
Mefloquine effectively treated falciparum malaria in 20 patients, achieving a 100% cure rate. While generally safe, mild side effects like nausea occurred, and patients require monitoring for potential late neuropsychiatric issues.
Area of Science:
- Tropical Medicine
- Pharmacology
Background:
- Falciparum malaria remains a significant global health concern.
- Mefloquine is an antimalarial drug used for treatment and prophylaxis.
- Understanding mefloquine's efficacy and safety profile is crucial for clinical practice.
Purpose of the Study:
- To evaluate the therapeutic effects of mefloquine in patients with falciparum malaria.
- To assess the side effect profile of mefloquine at a specific dosage.
- To determine the safety of mefloquine as a treatment for falciparum malaria.
Main Methods:
- An open prospective trial was conducted.
- Twenty patients diagnosed with falciparum malaria were enrolled.
- Mefloquine was administered at a total dose of 1500 mg base.
Main Results:
- A 100% cure rate was achieved in all patients.
- Fever and parasitemia resolved within 3 days of treatment.
- Common side effects included nausea and vomiting in 25% of patients; no neurological or psychiatric disorders were observed.
Conclusions:
- Mefloquine demonstrated high efficacy and a favorable safety profile at the tested dosage for falciparum malaria.
- Patients require regular follow-up due to the potential for late-onset neuropsychiatric side effects.
- Informing patients and families about potential risks is essential for safe mefloquine use.